Ivan Fazio
Ivan Fazio has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alessio Ciminna
CdC Torina, Palermo, Italy, Italy
1 shared publication - Antonella Mazzonello
Unità Operativa di Radioterapia Oncologica, Casa di Cura Macchiarella, 90138 Palermo, Italy
1 shared publication - Antonino Daidone
Radiation Oncology, CdC Villa Santa Teresa, Bagheria 90011, Palermo, Italy
1 shared publication - Daniela Sambataro
Medical Oncology, Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
1 shared publication - Dario Aiello
Radiation Oncology Division, Sacro Cuore Don Calabria Cancer Care Center, Negrar-Verona, Italy
1 shared publication - Giuseppa Scandurra
Medical Oncology, Department of Medicine and Surgery, Kore University of Enna, 94100 Enna, Italy
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by MDPI AG in Preprints.org
Observational Study on the Effectiveness of L‐Arginine Plus Vitamin C in the Management of Cancer‐Related Fatigue
Background/Objectives: Cancer-related fatigue is one of the most distressing symptoms complained by neoplastic patients. L-arginine has a positive effect on physical performance in normal individuals, on fatigue in diseases other than cancer and on immune response in cancer patients. Methods: Forty-four cancer patients undergoing medical treatment were treated with oral l-arginine 1.66 g and 500 mg of vitamin C b.i.d. Cancer-related fatigue and health-related quality of life were recorded before treatment and after 15 and 30 days employing a visual analog scale and the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) respectively. Results: Daily oral supplementation with l-arginine and vitamin C ameliorated cancer-related fatigue in a statistically significant manner. Health-related quality of life remained mostly unchanged despite patients had advanced cancer and were administered medical treatments including chemotherapy, immunotherapy and biologics. No effect on appetite preservation was observed but in a small percentage of patients Conclusions: Our exploratory study suggests a positive effect of oral supplementation with l-arginine plus vitamin C on cancer related fatigue without significant worsening of quality of life. Due to the heterogeneity of patients sample further studies are needed including more clinically homogenous groups of patients.
- 17 November 2025
- Published by MDPI AG in Preprints.org
Open AccessObservational Study on the Effectiveness of L‐Arginine Plus Vitamin C in the Management of Cancer‐Related Fatigue
Background/Objectives: Cancer-related fatigue is one of the most distressing symptoms complained by neoplastic patients. L-arginine has a positive effect on physical performance in normal individuals, on fatigue in diseases other than cancer and on immune response in cancer patients. Methods: Forty-four cancer patients undergoing medical treatment were treated with oral l-arginine 1.66 g and 500 mg of vitamin C b.i.d. Cancer-related fatigue and health-related quality of life were recorded before treatment and after 15 and 30 days employing a visual analog scale and the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) respectively. Results: Daily oral supplementation with l-arginine and vitamin C ameliorated cancer-related fatigue in a statistically significant manner. Health-related quality of life remained mostly unchanged despite patients had advanced cancer and were administered medical treatments including chemotherapy, immunotherapy and biologics. No effect on appetite preservation was observed but in a small percentage of patients Conclusions: Our exploratory study suggests a positive effect of oral supplementation with l-arginine plus vitamin C on cancer related fatigue without significant worsening of quality of life. Due to the heterogeneity of patients sample further studies are needed including more clinically homogenous groups of patients.
- Open Access
- 27 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1030
The Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.
- 27 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (10) , 1030
Open AccessThe Role of Stereotactic Body Radiotherapy (SBRT) in Oligoprogressive Renal Cell Carcinoma (RCC) Treated with ICIs–TKIs: A Retrospective Multicentric Study
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.